• 1
    Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095101
  • 2
    D’Amico AV, Desjardin A, Chung A et al. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer 1998; 82: 188796
  • 3
    Philip J, Dutta Roy S, Ballal M, Foster CS, Javle P. Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer? BJU Int 2005; 95: 96971
  • 4
    Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297301
  • 5
    Obek C, Louis P, Civantos F, Soloway MS. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 1999; 161: 4949
  • 6
    Cohen MS, Hanley RS, Kurteva T et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol 2008; 54: 37181
  • 7
    Magheli A, Hinz S, Hege C et al. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol 2010; 183: 12631
  • 8
    Moussa AS, Li J, Soriano M, Klein EA, Dong F, Jones JS. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 2009; 103: 438
  • 9
    Gofrit ON, Zorn KC, Taxy JB et al. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer. J Urol 2007; 178: 19258
  • 10
    Krane LS, Menon M, Kaul SA et al. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer. Urol Oncol 2009; doi:10.1016/j.urolonc. 2009.04.018
  • 11
    11 Tilki D, Schlenker B, John M et al. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series. Urol Oncol 2009; doi:10.1016/j.urolonc.2009.07.003
  • 12
    Muntener M, Epstein JI, Hernandez DJ et al. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 2008; 53: 76776
  • 13
    Serkin FB, Soderdahl DW, Cullen J, Chen Y, Hernandez J. Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7. Urol Oncol 2010; 28: 3027
  • 14
    Pinthus JH, Witkos M, Fleshner NE et al. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 2006; 176: 97984
  • 15
    Makarov DV, Trock BJ, Humphreys EB et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095101
  • 16
    D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 137683
  • 17
    Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 4339
  • 18
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15917